{"gene":"F10","run_date":"2026-04-28T17:46:03","timeline":{"discoveries":[{"year":1983,"finding":"The complete amino acid sequence of the light chain of human coagulation Factor X was determined, revealing 139 residues including 11 gamma-carboxyglutamic acid (Gla) residues; residue 63 was identified as L-erythro-beta-hydroxyaspartic acid, a novel post-translational modification not previously described in proteins.","method":"Automated Edman degradation of peptides from chemical and enzymatic digests, confirmed by proton NMR and mass spectrometry","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — direct protein sequencing with multiple orthogonal chemical methods; foundational structural characterization","pmids":["6871167"],"is_preprint":false},{"year":1984,"finding":"cDNA sequencing of human Factor X established that it is synthesized as a single-chain polypeptide containing both light and heavy chains connected by an Arg-Lys-Arg tripeptide; the two chains are then generated by cleavage of internal peptide bonds and linked by a disulfide bond in plasma. The heavy chain active site shows high DNA sequence identity with prothrombin and Factor IX.","method":"cDNA library screening with anti-Factor X antibody, DNA sequencing of positive clones","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — complete cDNA sequencing establishing biosynthetic mechanism; foundational study","pmids":["6587384"],"is_preprint":false},{"year":1986,"finding":"The gene organization of human Factor X was characterized, revealing seven introns and eight exons whose boundaries are essentially identical to those in Factor IX and protein C genes, with each exon encoding a discrete structural/functional domain (Gla domain, EGF-like domains, activation peptide, serine protease domain). This organization strongly supports evolution of vitamin K-dependent coagulation factors from a common ancestral gene.","method":"Recombinant bacteriophage isolation, DNA sequencing to map intron/exon boundaries","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — complete gene sequencing with structural domain mapping; foundational","pmids":["3768336"],"is_preprint":false},{"year":1988,"finding":"Factor Xa functions as a component of the prothrombinase complex, requiring cofactor Factor Va, phospholipid membrane surfaces, and calcium ions to efficiently cleave prothrombin to thrombin. Factor Xa's serine protease activity is the catalytic center of this complex.","method":"In vitro reconstitution of prothrombinase complex; kinetic enzyme assays","journal":"Annual review of biochemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstitution assays, extensively replicated; foundational review summarizing established mechanism","pmids":["3052293"],"is_preprint":false},{"year":1988,"finding":"The lipoprotein-associated coagulation inhibitor (LACI, later named TFPI) directly inhibits Factor Xa at or near its active site, forming a Factor Xa-LACI complex detectable by non-denaturing PAGE. This Xa-LACI complex is required for subsequent feedback inhibition of the Factor VIIa/tissue factor complex, requiring the Gla domain of Xa. Heparin accelerates Xa inhibition ~2.5-fold; phospholipid and Ca2+ slow it ~2.5-fold.","method":"Chromogenic substrate assays, bioassays, non-denaturing PAGE, SDS-PAGE complex visualization, use of Gla-domain-lacking BXa(-GD) construct","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 — in vitro enzyme assays with mutagenesis/domain deletion and multiple orthogonal methods; foundational mechanistic paper","pmids":["3422166"],"is_preprint":false},{"year":1990,"finding":"Tissue Factor Pathway Inhibitor (TFPI) regulates coagulation via a two-step mechanism: it first directly inhibits Factor Xa, then in a Factor Xa-dependent manner produces feedback inhibition of the Factor VIIa/tissue factor catalytic complex. This explains why both extrinsic and intrinsic coagulation pathways are clinically required for hemostasis.","method":"Kinetic inhibition assays, reconstituted coagulation system","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro with kinetic analysis; multiply replicated","pmids":["2271516"],"is_preprint":false},{"year":1993,"finding":"The crystal structure of human des(1-45) Factor Xa (lacking the Gla domain) was solved at 2.2 Å resolution, revealing: the catalytic domain fold is similar to alpha-thrombin; the second EGF-like module makes contacts with the catalytic domain; the C-terminal Arg of the A-chain interacts in a substrate-like manner with the S1 specificity pocket of a neighboring molecule; and there is a Ca2+-binding site in the catalytic domain. The structure also showed that the region corresponding to the fibrinogen recognition site of thrombin has reversed electrical polarity in Factor Xa.","method":"X-ray crystallography at 2.2 Å resolution, R-value 0.168; automated Edman degradation for fragment identity","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 — high-resolution crystal structure with rigorous refinement; foundational structural paper","pmids":["8355279"],"is_preprint":false},{"year":1994,"finding":"Protein S directly binds Factor Xa (Kd ~18-19 nM) independent of activated protein C, and directly inhibits Factor Xa amidolytic activity (~50% inhibition at 33 nM protein S). Protein S also inhibits prothrombin conversion by Factor Xa in a phospholipid-independent, Ca2+-stimulated manner. Protein S inhibition of prothrombinase was 2.3-fold more potent in the presence of Factor Va, with ~8 nM protein S causing 50% inhibition.","method":"Ligand blotting, immobilized protein binding assays, fluid-phase binding with Kd determination, amidolytic activity assays, one-stage clotting time assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal binding and functional assays; direct Kd measurements; strong evidence","pmids":["8146182"],"is_preprint":false},{"year":1984,"finding":"Protein C inhibitor (from human plasma) inhibits Factor Xa with an inhibition constant (Ki) of 3.1 × 10⁻⁷ M. The inhibitor forms an enzyme-inhibitor complex (apparent Mr ~102,000 non-reduced) with Factor Xa; heparin (5-10 units/ml) accelerates inhibition of activated protein C ~30-fold and also accelerates Factor Xa inhibition. The complex can be dissociated by ammonia or hydroxylamine, releasing active enzyme.","method":"Kinetic inhibition assays, SDS-PAGE of enzyme-inhibitor complexes, 125I-labeled inhibitor autoradiography","journal":"Journal of biochemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro enzyme kinetics with complex visualization and multiple proteases tested; rigorous","pmids":["6323392"],"is_preprint":false},{"year":1996,"finding":"The 3.0 Å crystal structure of human des-Gla Factor Xa in complex with the synthetic inhibitor DX-9065a revealed two principal binding interactions: the naphthamidine group forms a salt bridge with Asp-189 in the S1 pocket, and the pyrrolidine ring binds in a unique aryl-binding site (S4). Unlike thrombin inhibitor complexes, Gly-216 (S3) does not contribute hydrogen bonds. The S2 site is blocked by Tyr-99, distinguishing Factor Xa from thrombin. The S4 site is lined by carbonyl oxygens that accommodate positive charges.","method":"X-ray crystallography at 3.0 Å resolution with synthetic inhibitor complex","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — high-resolution crystal structure with inhibitor complex; defines substrate recognition mechanism","pmids":["8939944"],"is_preprint":false},{"year":2002,"finding":"A Glu19Ala mutation in the Gla domain of Factor X causes symptomatic CRMred Factor X deficiency by specifically impairing activation via the Factor VIIa/tissue factor (extrinsic) pathway: complete activation of recombinant 19Ala-FX required 30-fold higher Factor VIIa/TF concentration than wild-type. Activation by Factor IXa/VIIIa or Russell's viper venom (RVV), and thrombin generation activity, were comparable to wild-type, demonstrating the Gla domain mediates specific interaction with the extrinsic pathway.","method":"Recombinant protein expression, activation assays with purified Factor VIIa/TF, FIXa/FVIIIa, and RVV; thrombin generation assays; prothrombin time and APTT plasma assays","journal":"Thrombosis and haemostasis","confidence":"High","confidence_rationale":"Tier 1 — recombinant protein with defined mutation, multiple orthogonal activation assays; strong mechanistic evidence","pmids":["12195695"],"is_preprint":false},{"year":2003,"finding":"Factor Xa generation through the tissue factor pathway is the central event of hemostasis, with thrombin playing multiple autocatalytic and feedback roles in its own generation and inhibition. Two Factor Xa-generating complexes exist: the extrinsic tenase (Factor VIIa/TF) for initiation, and the intrinsic tenase (Factor IXa/VIIIa) for amplification/propagation; stoichiometric inhibitors (TFPI, antithrombin) and dynamic mechanisms regulate the process.","method":"Review integrating in vitro reconstitution and kinetic data from multiple studies","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"High","confidence_rationale":"Tier 1 — review of extensively replicated reconstitution and kinetic studies; strong preponderance of evidence","pmids":["12524220"],"is_preprint":false},{"year":2007,"finding":"A homozygous nonstop mutation (F10-Augusta) in the Factor X gene — combining an 8-bp insertion in 3'-genomic DNA and a 5-bp deletion in terminal exon 8 — results in complete absence of Factor X protein and severe hemorrhage. The mutant transcript lacks an in-frame stop codon, and its steady-state concentration is markedly lower than wild-type message, implicating the nonstop mRNA decay (NMD) surveillance pathway as the pathogenic mechanism reducing FX expression.","method":"Gene sequencing, RT-PCR, 3'-RACE, allele-specific RFLP assay comparing mutant vs. wild-type transcript levels in patient and heterozygous parent RNA","journal":"Thrombosis and haemostasis","confidence":"High","confidence_rationale":"Tier 2 — molecular characterization of patient mutation with mRNA surveillance mechanism; multiple molecular methods","pmids":["18064309"],"is_preprint":false},{"year":2008,"finding":"Coagulation Factor X (FX) binds to the adenovirus serotype 5 (Ad5) hexon protein — specifically to the hypervariable regions (HVRs) on the hexon surface — via an interaction between the FX Gla domain and hexon. The FX serine protease domain contains a heparin-binding exosite that mediates infection of hepatocytes. Cryo-electron microscopy and single-particle reconstruction localized the FX attachment site to the central depression at the top of the hexon trimer. Hexon-mutated virus with reduced FX binding failed to transduce hepatocytes in vivo.","method":"Affinity binding assays (FX binding affinity 229 pM by SPR), cryo-electron microscopy with single-particle image reconstruction, in vivo hepatocyte transduction with hexon-mutated virus","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1-2 — cryo-EM structure, affinity measurements, mutagenesis, in vivo validation; multiply replicated across two concurrent papers","pmids":["18267072","18391209"],"is_preprint":false},{"year":2009,"finding":"Systematic mutagenesis identified specific amino acids on Ad5 hexon HVR5 and HVR7 critical for FX binding: mutation of 2 amino acids in HVR5 or 4 amino acids in HVR7 (or a single mutation at position 451 in HVR7) was sufficient to ablate FX-mediated liver transduction in vitro and in vivo. FX binding requires the hexon HVR5 and HVR7 regions, as demonstrated by domain swapping with Ad26 (which does not bind FX).","method":"Surface plasmon resonance (SPR) binding assays, domain swapping between Ad5 and Ad26, site-directed mutagenesis, in vitro gene delivery, in vivo liver transduction","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1-2 — mutagenesis combined with SPR, in vitro and in vivo functional assays; strong evidence","pmids":["19429866"],"is_preprint":false},{"year":2009,"finding":"Factor X expression is locally upregulated in fibrotic lung tissue (bronchial and alveolar epithelia) in human idiopathic pulmonary fibrosis and murine bleomycin models. Locally produced FXa drives myofibroblast differentiation in primary human lung fibroblasts via TGF-beta activation mediated through proteinase-activated receptor-1 (PAR1) and integrin αvβ5. Direct FXa inhibition attenuated bleomycin-induced pulmonary fibrosis in mice, establishing a causal mechanistic link.","method":"Immunostaining of human biopsy specimens, in vitro myofibroblast differentiation assay with recombinant FXa, PAR1/integrin αvβ5 inhibitor studies, in vivo bleomycin mouse model with FXa inhibitor treatment","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — mechanistic pathway (FXa→PAR1/αvβ5→TGF-β→myofibroblast) established with inhibitors, in vitro and in vivo validation","pmids":["19652365"],"is_preprint":false},{"year":2010,"finding":"FX-binding ablated Ad5 vectors (with mutations abolishing hexon-FX interaction) show highly reduced liver transduction but preferentially localize to liver and spleen 1 hour post-injection, with spleen transduction (CD11c+, ER-TR7+, MAdCAM-1+ cells in the marginal zone) becoming more efficient at high doses. This demonstrates that FX binding is specifically required for hepatocyte transduction but not for initial hepatic/splenic biodistribution.","method":"In vivo biodistribution studies, immunohistochemistry with cell-type markers, transgene co-localization, macrophage depletion experiments","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — in vivo functional studies with FX-binding ablated vectors; mechanistically informative","pmids":["20610817"],"is_preprint":false},{"year":2023,"finding":"Factor X (FX) is upregulated in lung interstitial macrophages following gemcitabine chemotherapy, and activated FX (FXa) contributes to a pro-metastatic host response. Targeting FXa with an FXa inhibitor or F10 gene knockdown reduced chemotherapy-induced pro-metastatic effects, demonstrating that FXa in macrophages promotes breast cancer lung metastasis through interplay between coagulation and inflammation.","method":"Transgenic spontaneous breast cancer model, gemcitabine treatment, flow cytometry, CCR2 knockout, F10 gene knockdown with siRNA/shRNA, FXa inhibitor pharmacological treatment, in vivo metastasis quantification","journal":"JCI insight","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo genetic and pharmacological evidence; single study but multiple orthogonal approaches","pmids":["36976637"],"is_preprint":false}],"current_model":"Human coagulation Factor X (F10) is a vitamin K-dependent serine protease synthesized as a single-chain precursor with Gla, EGF, and catalytic domains encoded by an 8-exon gene; it is activated by cleavage via the extrinsic (FVIIa/TF) or intrinsic (FIXa/FVIIIa) tenase complexes — with the Gla domain specifically required for extrinsic pathway activation — and then functions as the catalytic subunit of the prothrombinase complex (with FVa, phospholipid, and Ca²⁺) to convert prothrombin to thrombin; FXa activity is regulated by direct inhibition from TFPI (forming a FXa-TFPI-FVIIa/TF quaternary complex), protein S (Kd ~18 nM), protein C inhibitor, and antithrombin; structurally, its active site S1 pocket binds Asp-189, a unique S4 aryl-binding site lined by carbonyl oxygens accommodates positive charges, and Tyr-99 blocks the S2 site; beyond coagulation, locally expressed FXa signals through PAR1 and integrin αvβ5 to activate TGF-β and drive myofibroblast differentiation in lung fibrosis, and FXa in macrophages can promote tumor metastasis."},"narrative":{"teleology":[{"year":1983,"claim":"Determination of the complete light-chain amino acid sequence resolved the primary structure of the Gla domain and identified a novel post-translational modification (β-hydroxyaspartic acid at residue 63), establishing the chemical basis for FX's calcium- and membrane-binding properties.","evidence":"Automated Edman degradation with NMR and mass spectrometry confirmation of purified human FX light chain","pmids":["6871167"],"confidence":"High","gaps":["Functional role of β-hydroxyaspartate at position 63 not established","Three-dimensional arrangement of Gla residues unknown at this stage"]},{"year":1984,"claim":"cDNA sequencing revealed that FX is synthesized as a single-chain precursor processed by cleavage of an internal Arg-Lys-Arg tripeptide into disulfide-linked light and heavy chains, establishing the biosynthetic pathway and confirming homology with other vitamin K-dependent proteases.","evidence":"cDNA library screening with anti-FX antibody and full-length sequencing","pmids":["6587384"],"confidence":"High","gaps":["Intracellular processing site(s) and responsible protease(s) not identified","Regulation of FX expression not addressed"]},{"year":1986,"claim":"Gene structure analysis showed eight exons with boundaries matching Factor IX and protein C, demonstrating that each exon encodes a discrete functional domain and supporting the model that vitamin K-dependent coagulation factors evolved from a common ancestral gene.","evidence":"Bacteriophage cloning and DNA sequencing of the entire F10 gene with intron/exon mapping","pmids":["3768336"],"confidence":"High","gaps":["Promoter and transcriptional regulation of F10 not characterized","No functional correlation between individual exon-encoded domains and activity"]},{"year":1988,"claim":"Reconstitution experiments established that FXa is the catalytic subunit of the prothrombinase complex and that TFPI (LACI) inhibits FXa directly, with the resulting FXa–TFPI complex required for feedback inhibition of FVIIa/TF — defining the central regulatory logic of coagulation initiation.","evidence":"In vitro prothrombinase reconstitution with kinetic assays; chromogenic and bioassay inhibition studies with Gla-domain-deleted FXa","pmids":["3052293","3422166","2271516"],"confidence":"High","gaps":["Structural basis of FXa–TFPI interaction unknown","In vivo stoichiometry and kinetics of quaternary complex not determined"]},{"year":1993,"claim":"The first crystal structure of human Factor Xa (des-Gla, 2.2 Å) revealed the catalytic domain fold, inter-domain contacts between EGF2 and the protease domain, a catalytic-domain Ca²⁺ site, and reversed electrostatic polarity at the fibrinogen-recognition-equivalent surface compared to thrombin — explaining FXa's distinct substrate specificity.","evidence":"X-ray crystallography at 2.2 Å resolution","pmids":["8355279"],"confidence":"High","gaps":["Full-length structure including Gla domain not obtained","No co-crystal with FVa or prothrombin substrate"]},{"year":1994,"claim":"Demonstration that protein S directly binds FXa (Kd ~18 nM) and inhibits its amidolytic and prothrombinase activities independently of activated protein C established a previously unrecognized anticoagulant mechanism operating through direct FXa regulation.","evidence":"Ligand blotting, fluid-phase binding assays, amidolytic and clotting assays with purified protein S and FXa","pmids":["8146182"],"confidence":"High","gaps":["Binding interface on FXa not mapped","Physiological relevance relative to APC-dependent pathway not quantified in vivo"]},{"year":1996,"claim":"Co-crystal structure of FXa with inhibitor DX-9065a defined the active-site architecture — S1 pocket salt bridge with Asp-189, a unique S4 aryl-binding site lined by carbonyl oxygens, and S2 blockage by Tyr-99 — providing the structural framework that distinguishes FXa from thrombin for selective drug design.","evidence":"X-ray crystallography at 3.0 Å with synthetic inhibitor complex","pmids":["8939944"],"confidence":"High","gaps":["No structure with macromolecular inhibitor (TFPI, antithrombin)","Dynamics of S4 pocket accommodation of diverse ligands not addressed"]},{"year":2002,"claim":"The Glu19Ala Gla-domain mutation demonstrated that a single residue change selectively abolishes extrinsic-pathway activation while leaving intrinsic-pathway activation intact, proving the Gla domain mediates a specific molecular interaction with the FVIIa/TF complex rather than simply anchoring FX to membranes.","evidence":"Recombinant FX mutant expression with activation assays using purified FVIIa/TF, FIXa/FVIIIa, and RVV","pmids":["12195695"],"confidence":"High","gaps":["Exact contact residues between Gla domain and TF/FVIIa not mapped structurally","Other Gla-domain residues contributing to extrinsic pathway specificity not systematically tested"]},{"year":2008,"claim":"Discovery that the FX Gla domain binds adenovirus serotype 5 hexon (Kd ~229 pM) and that the FX serine protease domain contains a heparin-binding exosite mediating hepatocyte entry revealed an unexpected role for a coagulation factor as a blood-borne bridge enabling viral liver tropism.","evidence":"SPR binding, cryo-EM single-particle reconstruction, hexon-mutant Ad5 with ablated FX binding, in vivo hepatocyte transduction assays","pmids":["18267072","18391209"],"confidence":"High","gaps":["Cellular receptor on hepatocytes engaged by FX-coated virus not identified","Whether other vitamin K-dependent factors can substitute for FX in vivo not tested"]},{"year":2009,"claim":"Two key mechanistic advances: (1) mutagenesis of hexon HVR5/HVR7 defined the minimal FX-binding determinants on the adenovirus surface, and (2) locally expressed FXa in fibrotic lung was shown to drive myofibroblast differentiation via PAR1 and integrin αvβ5–mediated TGF-β activation, establishing a non-hemostatic pro-fibrotic signaling axis.","evidence":"Domain swapping/site-directed mutagenesis of Ad5/Ad26 hexon with SPR and in vivo transduction; FXa treatment of primary human lung fibroblasts with PAR1/αvβ5 inhibitors; bleomycin mouse fibrosis model with FXa inhibitor","pmids":["19429866","19652365"],"confidence":"High","gaps":["Downstream signaling cascade between PAR1/αvβ5 and TGF-β activation not fully delineated","Whether FXa's fibrotic role extends beyond the lung not established","Hepatocyte receptor for FX-Ad5 complex remains unidentified"]},{"year":2023,"claim":"Identification of FX upregulation in lung interstitial macrophages after chemotherapy, with FXa promoting breast cancer lung metastasis, extended the non-hemostatic biology of FXa to tumor–immune crosstalk.","evidence":"Transgenic breast cancer model with gemcitabine, flow cytometry, F10 knockdown (siRNA/shRNA), FXa inhibitor, in vivo metastasis quantification","pmids":["36976637"],"confidence":"Medium","gaps":["Mechanism by which macrophage-derived FXa promotes metastasis (PAR signaling, ECM remodeling, or other) not defined","Generalizability beyond breast cancer lung metastasis not tested","Single study awaiting independent replication"]},{"year":null,"claim":"Key unresolved questions include: the structural basis of FXa interaction with FVa in the assembled prothrombinase complex, the identity of the hepatocyte receptor engaged by FX-coated adenovirus, the full signaling pathway linking macrophage FXa to metastatic niche formation, and whether FXa's non-hemostatic functions (fibrosis, metastasis) share a common PAR-dependent mechanism.","evidence":"","pmids":[],"confidence":"Low","gaps":["No high-resolution structure of full prothrombinase complex","Hepatocyte receptor for FX–Ad5 unknown","Common vs. distinct signaling of FXa in fibrosis and metastasis not compared"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[3,6,7,9,11]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[3,8,9]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[0,3,10]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[1,3,7,11]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[3,15]}],"pathway":[{"term_id":"R-HSA-109582","term_label":"Hemostasis","supporting_discovery_ids":[3,4,5,7,10,11]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[15,17]}],"complexes":["Prothrombinase complex (FXa/FVa/phospholipid/Ca²⁺)","FXa–TFPI–FVIIa/TF quaternary complex"],"partners":["F5","F2","TFPI","PROS1","F7","F3","SERPINA5"],"other_free_text":[]},"mechanistic_narrative":"Coagulation Factor X is a vitamin K-dependent serine protease that serves as the convergence point of the extrinsic and intrinsic coagulation pathways and, upon activation to Factor Xa, forms the catalytic subunit of the prothrombinase complex (with Factor Va, phospholipid, and Ca²⁺) to convert prothrombin to thrombin [PMID:3052293, PMID:12524220]. Synthesized as a single-chain precursor containing Gla, EGF-like, and serine protease domains, FX undergoes intracellular processing to a disulfide-linked two-chain zymogen; its Gla domain, which carries 11 γ-carboxyglutamic acid residues and a β-hydroxyaspartic acid at position 63, is specifically required for activation by the extrinsic tenase (FVIIa/tissue factor), as demonstrated by the Glu19Ala mutation that selectively impairs this pathway [PMID:6871167, PMID:6587384, PMID:12195695]. FXa activity is regulated by TFPI (which first inhibits FXa then uses the FXa–TFPI complex for feedback inhibition of FVIIa/TF), protein S (Kd ~18 nM, direct FXa inhibition independent of activated protein C), protein C inhibitor, and antithrombin [PMID:3422166, PMID:2271516, PMID:8146182, PMID:6323392]. Beyond hemostasis, locally expressed FXa in lung tissue signals through PAR1 and integrin αvβ5 to activate TGF-β and drive myofibroblast differentiation in pulmonary fibrosis, and FXa upregulated in lung interstitial macrophages promotes breast cancer metastasis [PMID:19652365, PMID:36976637]."},"prefetch_data":{"uniprot":{"accession":"P00742","full_name":"Coagulation factor X","aliases":["Stuart factor","Stuart-Prower factor"],"length_aa":488,"mass_kda":54.7,"function":"Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting (PubMed:22409427, PubMed:39880037). Factor Xa activates pro-inflammatory signaling pathways in a protease-activated receptor (PAR)-dependent manner (PubMed:24041930, PubMed:30568593, PubMed:34831181, PubMed:18202198). Up-regulates expression of protease-activated receptors (PARs) F2R, F2RL1 and F2RL2 in dermal microvascular endothelial cells (PubMed:35738824). Triggers the production of pro-inflammatory cytokines, such as MCP-1/CCL2 and IL6, in cardiac fibroblasts and umbilical vein endothelial cells in PAR-1/F2R-dependent manner (PubMed:30568593, PubMed:34831181). Triggers the production of pro-inflammatory cytokines, such as MCP-1/CCL2, IL6, TNF/TNF, IL-1beta/IL1B, IL8/CXCL8 and IL18, in endothelial cells and atrial tissues (PubMed:24041930, PubMed:35738824, PubMed:9780208). Induces expression of adhesion molecules, such as ICAM1, VCAM1 and SELE, in endothelial cells and atrial tissues (PubMed:24041930, PubMed:35738824, PubMed:9780208). Increases expression of phosphorylated ERK1/2 in dermal microvascular endothelial cells and atrial tissues (PubMed:24041930, PubMed:35738824). Triggers activation of the transcription factor NF-kappa-B in dermal microvascular endothelial cells and atrial tissues (PubMed:24041930, PubMed:35738824). Activates pro-inflammatory and pro-fibrotic responses in dermal fibroblasts and enhances wound healing probably via PAR-2/F2RL1-dependent mechanism (PubMed:18202198). Activates barrier protective signaling responses in endothelial cells in PAR-2/F2RL1-dependent manner; the activity depends on the cleavage of PAR-2/F2RL1 by factor Xa (PubMed:22409427). Up-regulates expression of plasminogen activator inhibitor 1 (SERPINE1) in atrial tissues (PubMed:24041930)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P00742/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/F10","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/F10","total_profiled":1310},"omim":[{"mim_id":"621535","title":"SPINOCEREBELLAR ATAXIA 52; SCA52","url":"https://www.omim.org/entry/621535"},{"mim_id":"621295","title":"CEREBRAL ARTERIOPATHY, AUTOSOMAL RECESSIVE, WITH SUBCORTICAL INFARCTS AND LEUKOENCEPHALOPATHY 1; CARASIL1","url":"https://www.omim.org/entry/621295"},{"mim_id":"620793","title":"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 29; LGMDR29","url":"https://www.omim.org/entry/620793"},{"mim_id":"619844","title":"INTELLECTUAL DEVELOPMENTAL DISORDER WITH OR WITHOUT PERIPHERAL NEUROPATHY; IDDPN","url":"https://www.omim.org/entry/619844"},{"mim_id":"617362","title":"DEAH-BOX HELICASE 37; DHX37","url":"https://www.omim.org/entry/617362"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"liver","ntpm":149.7}],"url":"https://www.proteinatlas.org/search/F10"},"hgnc":{"alias_symbol":["fX"],"prev_symbol":[]},"alphafold":{"accession":"P00742","domains":[{"cath_id":"2.10.25.10","chopping":"131-165","consensus_level":"high","plddt":92.0294,"start":131,"end":165},{"cath_id":"2.40.10.10","chopping":"238-327","consensus_level":"medium","plddt":93.7857,"start":238,"end":327},{"cath_id":"2.40.10.10","chopping":"345-459","consensus_level":"medium","plddt":88.4886,"start":345,"end":459}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P00742","model_url":"https://alphafold.ebi.ac.uk/files/AF-P00742-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P00742-F1-predicted_aligned_error_v6.png","plddt_mean":80.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=F10","jax_strain_url":"https://www.jax.org/strain/search?query=F10"},"sequence":{"accession":"P00742","fasta_url":"https://rest.uniprot.org/uniprotkb/P00742.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P00742/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P00742"}},"corpus_meta":[{"pmid":"1999398","id":"PMC_1999398","title":"Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable.","date":"1991","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1999398","citation_count":308,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19429866","id":"PMC_19429866","title":"Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19429866","citation_count":152,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10433242","id":"PMC_10433242","title":"Estrogen receptor-alpha detected on the plasma membrane of aldehyde-fixed GH3/B6/F10 rat pituitary tumor cells by enzyme-linked immunocytochemistry.","date":"1999","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/10433242","citation_count":148,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8910301","id":"PMC_8910301","title":"Synthesis of GDP-L-fucose by the human FX protein.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8910301","citation_count":146,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25084738","id":"PMC_25084738","title":"A review of exosome separation techniques and characterization of B16-F10 mouse melanoma exosomes with AF4-UV-MALS-DLS-TEM.","date":"2014","source":"Analytical and bioanalytical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25084738","citation_count":135,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20610817","id":"PMC_20610817","title":"Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20610817","citation_count":94,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23890760","id":"PMC_23890760","title":"Anthocyanin determination in blueberry extracts from various cultivars and their antiproliferative and apoptotic properties in B16-F10 metastatic murine melanoma cells.","date":"2013","source":"Phytochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23890760","citation_count":89,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9020101","id":"PMC_9020101","title":"Transforming growth factor-beta1 inhibits basal melanogenesis in B16/F10 mouse melanoma cells by increasing the rate of degradation of tyrosinase and tyrosinase-related protein-1.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9020101","citation_count":66,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10438817","id":"PMC_10438817","title":"Tyrosine phosphorylation of A17 during vaccinia virus infection: involvement of the H1 phosphatase and the F10 kinase.","date":"1999","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/10438817","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16489048","id":"PMC_16489048","title":"Embryonic stem cell-derived dendritic cells expressing glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-F10.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16489048","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28680383","id":"PMC_28680383","title":"Antiproliferative and proapoptotic activities of anthocyanin and anthocyanidin extracts from blueberry fruits on B16-F10 melanoma cells.","date":"2017","source":"Food & nutrition research","url":"https://pubmed.ncbi.nlm.nih.gov/28680383","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11830592","id":"PMC_11830592","title":"Pax3 down-regulation and shut-off of melanogenesis in melanoma B16/F10.9 by interleukin-6 receptor signaling.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11830592","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19479013","id":"PMC_19479013","title":"Alkylphenol xenoestrogens with varying carbon chain lengths differentially and potently activate signaling and functional responses in GH3/B6/F10 somatomammotropes.","date":"2008","source":"Environmental health perspectives","url":"https://pubmed.ncbi.nlm.nih.gov/19479013","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20624404","id":"PMC_20624404","title":"Antitumor properties of aloe-emodin and induction of transglutaminase 2 activity in B16-F10 melanoma cells.","date":"2010","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/20624404","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29033318","id":"PMC_29033318","title":"An Alkynyl-Fucose Halts Hepatoma Cell Migration and Invasion by Inhibiting GDP-Fucose-Synthesizing Enzyme FX, TSTA3.","date":"2017","source":"Cell chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/29033318","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23517603","id":"PMC_23517603","title":"Stress hormones promote growth of B16-F10 melanoma metastases: an interleukin 6- and glutathione-dependent mechanism.","date":"2013","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23517603","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36434514","id":"PMC_36434514","title":"A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX).","date":"2022","source":"Journal of neurodevelopmental disorders","url":"https://pubmed.ncbi.nlm.nih.gov/36434514","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15374970","id":"PMC_15374970","title":"Tumor-microenvironment interactions: the fucose-generating FX enzyme controls adhesive properties of colorectal cancer cells.","date":"2004","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/15374970","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11938455","id":"PMC_11938455","title":"Growth inhibition of established B16-F10 lung metastases by sequential aerosol delivery of p53 gene and 9-nitrocamptothecin.","date":"2002","source":"Gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/11938455","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27271988","id":"PMC_27271988","title":"Cytosolic DNA Sensor Upregulation Accompanies DNA Electrotransfer in B16.F10 Melanoma Cells.","date":"2016","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/27271988","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30523603","id":"PMC_30523603","title":"Potential Properties of Lactobacillus plantarum F-10 as a Bio-control Strategy for Wound Infections.","date":"2019","source":"Probiotics and antimicrobial proteins","url":"https://pubmed.ncbi.nlm.nih.gov/30523603","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27666939","id":"PMC_27666939","title":"FX knockout CHO hosts can express desired ratios of fucosylated or afucosylated antibodies with high titers and comparable product quality.","date":"2016","source":"Biotechnology and bioengineering","url":"https://pubmed.ncbi.nlm.nih.gov/27666939","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19952505","id":"PMC_19952505","title":"In vitro and in vivo evaluation of mutagenicity of fucoxanthin (FX) and its metabolite fucoxanthinol (FXOH).","date":"2009","source":"The Journal of toxicological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/19952505","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16716087","id":"PMC_16716087","title":"Identification of FX in the heliobacterial reaction center as a [4Fe-4S] cluster with an S = 3/2 ground spin state.","date":"2006","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16716087","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25449038","id":"PMC_25449038","title":"Hinokitiol, a tropolone derivative, inhibits mouse melanoma (B16-F10) cell migration and in vivo tumor formation.","date":"2014","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/25449038","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25407022","id":"PMC_25407022","title":"Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCR genes are associated with breast cancer: a case-control study.","date":"2014","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25407022","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25028548","id":"PMC_25028548","title":"Antitumor effect of iRGD-modified liposomes containing conjugated linoleic acid-paclitaxel (CLA-PTX) on B16-F10 melanoma.","date":"2014","source":"International journal of nanomedicine","url":"https://pubmed.ncbi.nlm.nih.gov/25028548","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12865923","id":"PMC_12865923","title":"Overexpression of a set of genes, including WISP-1, common to pulmonary metastases of both mouse D122 Lewis lung carcinoma and B16-F10.9 melanoma cell lines.","date":"2003","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12865923","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29510292","id":"PMC_29510292","title":"Thymoquinone Induces Apoptosis in B16-F10 Melanoma Cell Through Inhibition of p-STAT3 and Inhibits Tumor Growth in a Murine Intracerebral Melanoma Model.","date":"2018","source":"World neurosurgery","url":"https://pubmed.ncbi.nlm.nih.gov/29510292","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29219021","id":"PMC_29219021","title":"Review of the Mechanism of Action for Supartz FX in Knee Osteoarthritis.","date":"2016","source":"Cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/29219021","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14671107","id":"PMC_14671107","title":"Evidence for an essential catalytic role of the F10 protein kinase in vaccinia virus morphogenesis.","date":"2004","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/14671107","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25465225","id":"PMC_25465225","title":"Growth and metastasis of B16-F10 melanoma cells is not critically dependent on host CD73 expression in mice.","date":"2014","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25465225","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8753779","id":"PMC_8753779","title":"Decreased expression of a single tropomyosin isoform, TM5/TM30nm, results in reduction in motility of highly metastatic B16-F10 mouse melanoma cells.","date":"1996","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/8753779","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31866503","id":"PMC_31866503","title":"Single injection of IL-12 coacervate as an effective therapy against B16-F10 melanoma in mice.","date":"2019","source":"Journal of controlled release : official journal of the Controlled Release Society","url":"https://pubmed.ncbi.nlm.nih.gov/31866503","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28789929","id":"PMC_28789929","title":"Commentary on: \"Comprehensive transcriptional analysis of early-stage urothelial carcinoma.\" Hedegaard J, Lamy P, Nordentoft I, Algaba F, Høyer S, Ulhøi BP, Vang S, Reinert T, Hermann GG, Mogensen K, Thomsen MB, Nielsen MM, Marquez M, Segersten U, Aine M, Höglund M, Birkenkamp-Demtröder K, Fristrup N, Borre M, Hartmann A, Stöhr R, Wach S, Keck B, Seitz AK, Nawroth R, Maurer T, Tulic C, Simic T, Junker K, Horstmann M, Harving N, Petersen AC, Calle ML, Steyerberg EW, Beukers W, van Kessel KE, Jensen JB, Pedersen JS, Malmström PU, Malats N, Real FX, Zwarthoff EC, Ørntoft TF, Dyrskjøt L. Cancer Cell. 2016 Jul 11;30(1):27-42.","date":"2017","source":"Urologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28789929","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24593964","id":"PMC_24593964","title":"A lectin from Bothrops leucurus snake venom raises cytosolic calcium levels and promotes B16-F10 melanoma necrotic cell death via mitochondrial permeability transition.","date":"2014","source":"Toxicon : official journal of the International Society on Toxinology","url":"https://pubmed.ncbi.nlm.nih.gov/24593964","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25203554","id":"PMC_25203554","title":"Wogonin suppresses melanoma cell B16-F10 invasion and migration by inhibiting Ras-medicated pathways.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25203554","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34139572","id":"PMC_34139572","title":"Gene electrotransfer of IL-2 and IL-12 plasmids effectively eradicated murine B16.F10 melanoma.","date":"2021","source":"Bioelectrochemistry (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/34139572","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30541938","id":"PMC_30541938","title":"Comprehensive Evaluation of Compendial USP<71>, BacT/Alert Dual-T, and Bactec FX for Detection of Product Sterility Testing Contaminants.","date":"2019","source":"Journal of clinical microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/30541938","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30097108","id":"PMC_30097108","title":"Hydroalcoholic extract of Spartium junceum L. flowers inhibits growth and melanogenesis in B16-F10 cells by inducing senescence.","date":"2018","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30097108","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30545008","id":"PMC_30545008","title":"Melanogenesis Inhibitors from the Rhizoma of Ligusticum Sinense in B16-F10 Melanoma Cells In Vitro and Zebrafish In Vivo.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30545008","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7794897","id":"PMC_7794897","title":"Evidence for a mixed-ligand [4Fe-4S] cluster in the C14D mutant of PsaC. Altered reduction potentials and EPR spectral properties of the FA and FB clusters on rebinding to the P700-FX core.","date":"1995","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7794897","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22863076","id":"PMC_22863076","title":"Linking αMSH with PPARγ in B16-F10 melanoma.","date":"2012","source":"Pigment cell & melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/22863076","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10465579","id":"PMC_10465579","title":"Cytostatic activity of coumarin metabolites and derivatives in the B16-F10 murine melanoma cell line.","date":"1999","source":"Melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/10465579","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16700542","id":"PMC_16700542","title":"ESR signal of the iron-sulfur center F(X) and its function in the homodimeric reaction center of Heliobacterium modesticaldum.","date":"2006","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16700542","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25596038","id":"PMC_25596038","title":"Ilexgenin A induces B16-F10 melanoma cell G1/S arrest in vitro and reduces tumor growth in vivo.","date":"2015","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/25596038","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9247310","id":"PMC_9247310","title":"Unmasking by soluble IL-6 receptor of IL-6 effect on metastatic melanoma: growth inhibition and differentiation of B16-F10.9 tumor cells.","date":"1997","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9247310","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19765307","id":"PMC_19765307","title":"Proliferative and anti-proliferative effects of dietary levels of phytoestrogens in rat pituitary GH3/B6/F10 cells - the involvement of rapidly activated kinases and caspases.","date":"2009","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19765307","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20332452","id":"PMC_20332452","title":"Anthraquinones danthron and quinizarin exert antiproliferative and antimetastatic activity on murine B16-F10 melanoma cells.","date":"2010","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/20332452","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23462381","id":"PMC_23462381","title":"Modulation of membrane phospholipids, the cytosolic calcium influx and cell proliferation following treatment of B16-F10 cells with recombinant phospholipase-D from Loxosceles intermedia (brown spider) venom.","date":"2013","source":"Toxicon : official journal of the International Society on Toxinology","url":"https://pubmed.ncbi.nlm.nih.gov/23462381","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3917273","id":"PMC_3917273","title":"Inhibition of recombinant interferon-gamma-induced Ia antigen expression by shed B16 F10 melanoma cell membrane vesicles.","date":"1985","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/3917273","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25019992","id":"PMC_25019992","title":"Inhibition of cell proliferation, migration and invasion of B16-F10 melanoma cells by α-mangostin.","date":"2014","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/25019992","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24613382","id":"PMC_24613382","title":"Metastatic potential of B16-F10 melanoma cells is enhanced by extracellular S100A4 derived from RAW264.7 macrophages.","date":"2014","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/24613382","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12195695","id":"PMC_12195695","title":"Reduced activation of the Gla19Ala FX variant via the extrinsic coagulation pathway results in symptomatic CRMred FX deficiency.","date":"2002","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/12195695","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17725326","id":"PMC_17725326","title":"Contributions of the protein environment to the midpoint potentials of the A1 phylloquinones and the Fx iron-sulfur cluster in photosystem I.","date":"2007","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17725326","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30613833","id":"PMC_30613833","title":"Improved potency of F10 relative to 5-fluorouracil in colorectal cancer cells with p53 mutations.","date":"2018","source":"Cancer drug resistance (Alhambra, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/30613833","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15203909","id":"PMC_15203909","title":"Modifications in the head group and in the spacer of cholesterol-based cationic lipids promote transfection in melanoma B16-F10 cells and tumours.","date":"2004","source":"Journal of drug targeting","url":"https://pubmed.ncbi.nlm.nih.gov/15203909","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32245029","id":"PMC_32245029","title":"Anti-Melanogenic Effect of Ethanolic Extract of Sorghum bicolor on IBMX-Induced Melanogenesis in B16/F10 Melanoma Cells.","date":"2020","source":"Nutrients","url":"https://pubmed.ncbi.nlm.nih.gov/32245029","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27927165","id":"PMC_27927165","title":"Innate immunity based cancer immunotherapy: B16-F10 murine melanoma model.","date":"2016","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/27927165","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28084540","id":"PMC_28084540","title":"Peroxisome proliferator-activated receptor α (PPARα) contributes to control of melanogenesis in B16 F10 melanoma cells.","date":"2017","source":"Archives of dermatological research","url":"https://pubmed.ncbi.nlm.nih.gov/28084540","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8515877","id":"PMC_8515877","title":"Prominent expression of the actin-sequestering peptide Fx gene in the hippocampal region of rat brain.","date":"1993","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/8515877","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18835244","id":"PMC_18835244","title":"Unifying principles in homodimeric type I photosynthetic reaction centers: properties of PscB and the FA, FB and FX iron-sulfur clusters in green sulfur bacteria.","date":"2008","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/18835244","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27864061","id":"PMC_27864061","title":"Melanogenesis inhibits respiration in B16-F10 melanoma cells whereas enhances mitochondrial cell content.","date":"2016","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/27864061","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3132343","id":"PMC_3132343","title":"IFN-treatment of B16-F1 versus B16-F10: relative impact on non-adaptive and T-cell-mediated immune defense in metastatic spread.","date":"1988","source":"Clinical & experimental metastasis","url":"https://pubmed.ncbi.nlm.nih.gov/3132343","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18081833","id":"PMC_18081833","title":"Congenital FX deficiency combined with other clotting defects or with other abnormalities: a critical evaluation of the literature.","date":"2007","source":"Haemophilia : the official journal of the World Federation of Hemophilia","url":"https://pubmed.ncbi.nlm.nih.gov/18081833","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27698928","id":"PMC_27698928","title":"Phenylethanoid Glycosides from Cistanche tubulosa Inhibits the Growth of B16-F10 Cells both in Vitro and in Vivo by Induction of Apoptosis via Mitochondria-dependent Pathway.","date":"2016","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/27698928","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25510486","id":"PMC_25510486","title":"Thymineless death in F10-treated AML cells occurs via lipid raft depletion and Fas/FasL co-localization in the plasma membrane with activation of the extrinsic apoptotic pathway.","date":"2014","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/25510486","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22902646","id":"PMC_22902646","title":"Synthetic phosphoethanolamine a precursor of membrane phospholipids reduce tumor growth in mice bearing melanoma B16-F10 and in vitro induce apoptosis and arrest in G2/M phase.","date":"2012","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/22902646","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30046339","id":"PMC_30046339","title":"Ginkgo biloba Exocarp Extract Inhibits the Metastasis of B16-F10 Melanoma Involving PI3K/Akt/NF-κB/MMP-9 Signaling Pathway.","date":"2018","source":"Evidence-based complementary and alternative medicine : eCAM","url":"https://pubmed.ncbi.nlm.nih.gov/30046339","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17189827","id":"PMC_17189827","title":"Novel role of IL-6/SIL-6R signaling in the expression of inducible nitric oxide synthase (iNOS) in murine B16, metastatic melanoma clone F10.9, cells.","date":"2006","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17189827","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29317734","id":"PMC_29317734","title":"Combined SEP and anti-PD-L1 antibody produces a synergistic antitumor effect in B16-F10 melanoma-bearing mice.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29317734","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22532856","id":"PMC_22532856","title":"Acute and long-term effects of hyperthermia in B16-F10 melanoma cells.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22532856","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18392453","id":"PMC_18392453","title":"Paullinia cupana Mart var. sorbilis, guaraná, reduces cell proliferation and increases apoptosis of B16/F10 melanoma lung metastases in mice.","date":"2008","source":"Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas","url":"https://pubmed.ncbi.nlm.nih.gov/18392453","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37522672","id":"PMC_37522672","title":"Targeting the monocarboxylate transporter MCT2 and lactate dehydrogenase A LDHA in cancer cells with FX-11 and AR-C155858 inhibitors.","date":"2023","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37522672","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24441744","id":"PMC_24441744","title":"Cytotoxicity of lipophilic statins depends on their combined actions on HIF-1α expression and redox status in B16.F10 melanoma cells.","date":"2014","source":"Anti-cancer drugs","url":"https://pubmed.ncbi.nlm.nih.gov/24441744","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18064309","id":"PMC_18064309","title":"A nonstop mutation in the factor (F)X gene of a severely haemorrhagic patient with complete absence of coagulation FX.","date":"2007","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/18064309","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37626086","id":"PMC_37626086","title":"Inhibition of cancer-type amino acid transporter LAT1 suppresses B16-F10 melanoma metastasis in mouse models.","date":"2023","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/37626086","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23423894","id":"PMC_23423894","title":"FX cloning: a versatile high-throughput cloning system for characterization of enzyme variants.","date":"2013","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/23423894","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33547501","id":"PMC_33547501","title":"0D/2D heteronanostructure-integrated bimetallic CoCu-ZIF nanosheets and MXene-derived carbon dots for impedimetric cytosensing of melanoma B16-F10 cells.","date":"2021","source":"Mikrochimica acta","url":"https://pubmed.ncbi.nlm.nih.gov/33547501","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26965493","id":"PMC_26965493","title":"DTDP-rhamnosyl transferase RfbF, is a newfound receptor-related regulatory protein for phage phiYe-F10 specific for Yersinia enterocolitica serotype O:3.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26965493","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31054338","id":"PMC_31054338","title":"Thymoquinone Enhances the Effect of Gamma Knife in B16-F10 Melanoma Through Inhibition of Phosphorylated STAT3.","date":"2019","source":"World neurosurgery","url":"https://pubmed.ncbi.nlm.nih.gov/31054338","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26141996","id":"PMC_26141996","title":"Anti-melanogenesis and antigenotoxic activities of eriodictyol in murine melanoma (B16-F10) and primary human keratinocyte cells.","date":"2015","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/26141996","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26159852","id":"PMC_26159852","title":"Antineoplastic effects of Rhodiola crenulata treatment on B16-F10 melanoma.","date":"2015","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26159852","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23743169","id":"PMC_23743169","title":"Inhibition of metastatic potential of B16-F10 melanoma cell line in vivo and in vitro by biflorin.","date":"2013","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/23743169","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11831876","id":"PMC_11831876","title":"The FX enzyme is a functional component of lymphocyte activation.","date":"2001","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11831876","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31894337","id":"PMC_31894337","title":"Phellinus gilvus‑derived protocatechualdehyde induces G0/G1 phase arrest and apoptosis in murine B16‑F10 cells.","date":"2019","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/31894337","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16713660","id":"PMC_16713660","title":"GM-CSF-surface-modified B16.F10 melanoma cell vaccine.","date":"2006","source":"Vaccine","url":"https://pubmed.ncbi.nlm.nih.gov/16713660","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36358950","id":"PMC_36358950","title":"Combination Therapy of Curcumin and Disulfiram Synergistically Inhibits the Growth of B16-F10 Melanoma Cells by Inducing Oxidative Stress.","date":"2022","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/36358950","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31421440","id":"PMC_31421440","title":"Evaluation of [11C]KB631 as a PET tracer for in vivo visualisation of HDAC6 in B16.F10 melanoma.","date":"2019","source":"Nuclear medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/31421440","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28645635","id":"PMC_28645635","title":"Cytotoxicity of the coagulant Moringa oleifera lectin (cMoL) to B16-F10 melanoma cells.","date":"2017","source":"Toxicology in vitro : an international journal published in association with BIBRA","url":"https://pubmed.ncbi.nlm.nih.gov/28645635","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36976637","id":"PMC_36976637","title":"Reactive myelopoiesis and FX-expressing macrophages triggered by chemotherapy promote cancer lung metastasis.","date":"2023","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/36976637","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29879868","id":"PMC_29879868","title":"Upregulation of DNA Sensors in B16.F10 Melanoma Spheroid Cells After Electrotransfer of pDNA.","date":"2018","source":"Technology in cancer research & treatment","url":"https://pubmed.ncbi.nlm.nih.gov/29879868","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32678152","id":"PMC_32678152","title":"FMR1 mRNA from full mutation alleles is associated with ABC-CFX scores in males with fragile X syndrome.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32678152","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30698192","id":"PMC_30698192","title":"Uncovering the anti-proliferation mechanism and bioactive compounds in red kidney bean coat against B16-F10 melanoma cells by metabolomics and network pharmacology analysis.","date":"2019","source":"Food & function","url":"https://pubmed.ncbi.nlm.nih.gov/30698192","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30084054","id":"PMC_30084054","title":"Cycloartane triterpenoid (23R, 24E)-23-acetoxymangiferonic acid inhibited proliferation and migration in B16-F10 melanoma via MITF downregulation caused by inhibition of both β-catenin and c-Raf-MEK1-ERK signaling axis.","date":"2018","source":"Journal of natural medicines","url":"https://pubmed.ncbi.nlm.nih.gov/30084054","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18688565","id":"PMC_18688565","title":"Role of transglutaminase 2 in quercetin-induced differentiation of B16-F10 murine melanoma cells.","date":"2008","source":"Amino acids","url":"https://pubmed.ncbi.nlm.nih.gov/18688565","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19645856","id":"PMC_19645856","title":"Regression of established subcutaneous B16-F10 murine melanoma tumors after gef gene therapy associated with the mitochondrial apoptotic pathway.","date":"2009","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/19645856","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29707136","id":"PMC_29707136","title":"BNIP3 modulates the interface between B16-F10 melanoma cells and immune cells.","date":"2018","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29707136","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26020060","id":"PMC_26020060","title":"F10 Inhibits Growth of PC3 Xenografts and Enhances the Effects of Radiation Therapy.","date":"2014","source":"Journal of clinical oncology and research","url":"https://pubmed.ncbi.nlm.nih.gov/26020060","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31918014","id":"PMC_31918014","title":"Himachalol induces apoptosis in B16-F10 murine melanoma cells and protects against skin carcinogenesis.","date":"2020","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31918014","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16169070","id":"PMC_16169070","title":"A human protein-protein interaction network: a resource for annotating the proteome.","date":"2005","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/16169070","citation_count":1704,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10391209","id":"PMC_10391209","title":"Characterization of single-nucleotide polymorphisms in coding regions of human genes.","date":"1999","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10391209","citation_count":1381,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14718574","id":"PMC_14718574","title":"The human plasma proteome: a nonredundant list developed by combination of four separate sources.","date":"2004","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/14718574","citation_count":658,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3052293","id":"PMC_3052293","title":"Cofactor proteins in the assembly and expression of blood clotting enzyme complexes.","date":"1988","source":"Annual review of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/3052293","citation_count":534,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18267072","id":"PMC_18267072","title":"Adenovirus serotype 5 hexon mediates liver gene transfer.","date":"2008","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/18267072","citation_count":526,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3422166","id":"PMC_3422166","title":"The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action.","date":"1988","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/3422166","citation_count":481,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12524220","id":"PMC_12524220","title":"The dynamics of thrombin formation.","date":"2003","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12524220","citation_count":387,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8355279","id":"PMC_8355279","title":"Structure of human des(1-45) factor Xa at 2.2 A resolution.","date":"1993","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8355279","citation_count":385,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20135059","id":"PMC_20135059","title":"Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.","date":"2010","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/20135059","citation_count":384,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2271516","id":"PMC_2271516","title":"Regulation of coagulation by a multivalent Kunitz-type inhibitor.","date":"1990","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2271516","citation_count":381,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20978714","id":"PMC_20978714","title":"Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.","date":"2010","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/20978714","citation_count":302,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18391209","id":"PMC_18391209","title":"Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo.","date":"2008","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/18391209","citation_count":289,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20694273","id":"PMC_20694273","title":"Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation.","date":"2010","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/20694273","citation_count":284,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8939944","id":"PMC_8939944","title":"X-ray structure of active site-inhibited clotting factor Xa. Implications for drug design and substrate recognition.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8939944","citation_count":261,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19652365","id":"PMC_19652365","title":"Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury.","date":"2009","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/19652365","citation_count":260,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20946166","id":"PMC_20946166","title":"Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays.","date":"2011","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/20946166","citation_count":247,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7598447","id":"PMC_7598447","title":"Tissue factor pathway inhibitor and the revised theory of coagulation.","date":"1995","source":"Annual review of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/7598447","citation_count":233,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16580898","id":"PMC_16580898","title":"Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.","date":"2006","source":"Clinical pharmacology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/16580898","citation_count":219,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3768336","id":"PMC_3768336","title":"Gene for human factor X: a blood coagulation factor whose gene organization is essentially identical with that of factor IX and protein C.","date":"1986","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/3768336","citation_count":218,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8460120","id":"PMC_8460120","title":"Identification of a region of beta 2-glycoprotein I critical for lipid binding and anti-cardiolipin antibody cofactor activity.","date":"1993","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8460120","citation_count":185,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19913121","id":"PMC_19913121","title":"Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip.","date":"2009","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19913121","citation_count":164,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8146182","id":"PMC_8146182","title":"Protein S binds to and inhibits factor Xa.","date":"1994","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8146182","citation_count":160,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"6871167","id":"PMC_6871167","title":"Complete amino acid sequence of the light chain of human blood coagulation factor X: evidence for identification of residue 63 as beta-hydroxyaspartic acid.","date":"1983","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/6871167","citation_count":151,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"6587384","id":"PMC_6587384","title":"Characterization of a cDNA coding for human factor X.","date":"1984","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/6587384","citation_count":147,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"6323392","id":"PMC_6323392","title":"Mechanism of inhibition of activated protein C by protein C inhibitor.","date":"1984","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/6323392","citation_count":145,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53427,"output_tokens":2061,"usd":0.095598},"stage2":{"model":"claude-opus-4-6","input_tokens":5338,"output_tokens":1273,"usd":0.087773},"total_usd":0.517498,"stage1_batch_id":"msgbatch_0118RScg3WGaGkaZRtWZbtce","stage2_batch_id":"msgbatch_01Cpfzvtbj42aqp5oYZ5Te2s","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":66871,"output_tokens":5921,"usd":0.144714},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":8760,"output_tokens":3299,"usd":0.189413}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"The human FX protein (encoded by TSTA3/FX) is a bifunctional NADPH-dependent enzyme that catalyzes the final step of GDP-L-fucose synthesis from GDP-D-mannose, specifically converting GDP-4-keto-6-D-deoxymannose to GDP-L-fucose via a combined epimerase and reductase reaction.\",\n      \"method\": \"Purification of FX from human erythrocytes, cDNA sequencing revealing homology to E. coli Yefb, in vitro enzymatic assay with purified protein demonstrating NADPH-dependent reductase/epimerase activity\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — purified protein, in vitro enzymatic reconstitution, sequence homology corroboration\",\n      \"pmids\": [\"8910301\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"The FX enzyme (GDP-fucose synthase) regulates the expression of selectin ligands (sialyl Lewis-a) on colorectal cancer cells and controls their adhesive capacity to activated endothelial cells and recombinant E-selectin; overexpression of FX increased adhesion while siRNA knockdown decreased adhesion and global fucosylation.\",\n      \"method\": \"FX cDNA overexpression and siRNA knockdown in colorectal cancer cells, adhesion assays to endothelial cells and recombinant E-selectin, flow cytometry for selectin ligand expression\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal gain/loss-of-function experiments with defined cellular phenotype readout\",\n      \"pmids\": [\"15374970\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"FX enzyme expression is upregulated by polyclonal activation of T and B cells, and FX antisense oligonucleotide treatment reduces expression of fucosylated selectin ligands sLe-x and CLA upon lymphocyte activation, demonstrating FX is required for biosynthesis of selectin ligands in lymphocytes.\",\n      \"method\": \"Polyclonal lymphocyte activation assays, antisense oligonucleotide knockdown of FX, flow cytometry for selectin ligand expression\",\n      \"journal\": \"Cellular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — knockdown with specific functional readout, single lab\",\n      \"pmids\": [\"11831876\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"The alkynyl-fucose analog 6-alkynyl-fucose (6-Alk-Fuc) directly targets FX (TSTA3), the bifunctional GDP-fucose synthase, depleting cellular GDP-fucose and potently inhibiting cellular fucosylation; FX was identified as the direct molecular target by pull-down/chemical probe approach.\",\n      \"method\": \"Lectin and mass spectrometry glycan analysis, chemical probe (6-Alk-Fuc) target identification for FX, hepatoma cell invasion assays\",\n      \"journal\": \"Cell chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct target identification with chemical probe, orthogonal glycan analysis methods\",\n      \"pmids\": [\"29033318\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"FX knockout CHO cells cannot synthesize GDP-fucose de novo, resulting in fully afucosylated antibodies; addition of exogenous fucose to culture media rescues fucosylation, demonstrating FX is the essential enzyme for de novo GDP-fucose biosynthesis in mammalian cells.\",\n      \"method\": \"FX gene knockout in CHO cells, antibody glycan analysis by mass spectrometry, fucose supplementation rescue experiments\",\n      \"journal\": \"Biotechnology and bioengineering\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined biochemical phenotype and rescue, industrial validation\",\n      \"pmids\": [\"27666939\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Coagulation factor X (F10) is upregulated in lung interstitial macrophages following chemotherapy treatment, and targeting activated FXa with an FXa inhibitor or F10 gene knockdown reduces the pro-metastatic effect of chemotherapy, placing F10 in a coagulation-inflammation interplay in the lung metastatic niche.\",\n      \"method\": \"Transgenic spontaneous breast cancer mouse model, F10 gene knockdown, FXa inhibitor treatment, macrophage accumulation and metastasis quantification\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gene knockdown and pharmacological inhibition with defined in vivo metastasis phenotype, single study\",\n      \"pmids\": [\"36976637\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The Glu19Ala mutation in the gamma-carboxyglutamic acid (Gla) domain of coagulation factor X (FX) specifically impairs activation by the factor VIIa/tissue factor (TF) extrinsic pathway (requiring 30-fold higher FVIIa/TF concentration), while activation by factor IXa/VIIIa or Russell's viper venom is unaffected, demonstrating the Gla domain is essential for extrinsic pathway FX activation.\",\n      \"method\": \"Recombinant 19Ala-FX expression and characterization, activation assays with FVIIa/TF, FIXa/FVIIIa, and RVV, thrombin generation assays, plasma reconstitution\",\n      \"journal\": \"Thrombosis and haemostasis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — recombinant protein, in vitro functional assays with mutagenesis, orthogonal activation pathway comparisons\",\n      \"pmids\": [\"12195695\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"A nonstop mutation in the F10 gene (F10-Augusta) — an 8bp insertion plus 5bp terminal exon-8 deletion — eliminates the stop codon, leading to a markedly reduced steady-state mutant FX transcript (via nonstop mRNA decay), resulting in complete absence of FX protein and severe hemorrhagic phenotype.\",\n      \"method\": \"Gene sequencing, RT-PCR, 3'-RACE, allele-specific RFLP assay comparing mutant and wild-type transcript levels in patient and heterozygous parent RNA\",\n      \"journal\": \"Thrombosis and haemostasis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — molecular characterization of loss-of-function mutation with mRNA surveillance mechanism identified, single patient/study\",\n      \"pmids\": [\"18064309\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"The human FX protein (TSTA3/GDP-fucose synthase) is a homodimeric, NADPH-dependent bifunctional enzyme that converts GDP-4-keto-6-D-deoxymannose to GDP-L-fucose (via epimerase and reductase activities), serving as the rate-limiting step for de novo GDP-fucose biosynthesis; this activity controls global cellular fucosylation, the expression of selectin ligands on cancer cells and lymphocytes, and cell-endothelial adhesion relevant to metastasis, while the coagulation factor X (gene F10) is a serine protease with a Gla domain essential for activation via the extrinsic (VIIa/TF) pathway and plays a role in coagulation-driven pro-metastatic macrophage responses in the lung.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll systematically classify each paper before extracting discoveries.\n\n**Classification of key papers:**\n\n- Papers about B16-F10 melanoma cell line: EXCLUDE (F10 here is a melanoma clone designation, not the F10/coagulation factor X gene)\n- Papers about vaccinia virus F10 kinase (PMID:10438817, 14671107): EXCLUDE - Symbol collision; vaccinia F10 is a viral protein kinase unrelated to human coagulation factor X\n- Papers about FX as GDP-fucose synthase/TSTA3 (PMID:8910301, 29033318, 15374970, 11831876): EXCLUDE - These describe a different protein named \"FX\" (TSTA3/GDP-fucose synthase), not coagulation Factor X (F10 gene)\n- Papers about photosystem I FX iron-sulfur cluster: EXCLUDE - Symbol collision (plant/bacterial photosynthesis)\n- Papers about adenovirus hexon binding to coagulation FX (PMID:19429866, 20610817, 18267072, 18391209): KEEP - These directly describe coagulation Factor X (F10 gene product) interactions\n- Papers about coagulation Factor X structure, function, gene (PMID:8355279, 8939944, 3052293, 12524220, 3422166, 2271516, 7598447, 6587384, 3768336, 6871167): KEEP\n- PMID:12195695 (Gla19Ala FX variant): KEEP\n- PMID:18064309 (nonstop mutation F10): KEEP\n- PMID:18081833 (combined FX deficiency): KEEP - but mostly clinical, minimal mechanism\n- PMID:19652365 (FX in lung fibrosis via PAR1): KEEP\n- PMID:36976637 (FX in macrophages, chemotherapy metastasis): KEEP\n- PMID:27666939 (FX knockout CHO): borderline - describes FX enzyme for fucosylation in CHO context - this is TSTA3/FX not coagulation F10. EXCLUDE\n- PMID:25407022 (SNPs in F10 gene, breast cancer): minimal mechanism - EXCLUDE\n- PMID:8146182 (protein S binds/inhibits FXa): KEEP\n- PMID:6323392 (protein C inhibitor inhibits FXa): KEEP\n- PMID:7794897 (photosystem PsaC): EXCLUDE\n- PMID:16700542, 18835244, 16716087: EXCLUDE (photosystem)\n- PMID:30613833 (F10 fluoropyrimidine drug): EXCLUDE - \"F10\" here is a drug name\n- PMID:25510486 (F10 fluoropyrimidine AML): EXCLUDE - drug\n- PMID:26020060 (F10 fluoropyrimidine prostate): EXCLUDE - drug\n- PMID:1999398 (thymosin beta4/Fx actin): EXCLUDE - different protein\n- PMID:8515877 (Fx actin-sequestering brain): EXCLUDE\n- PMID:3917273, others about B16-F10: EXCLUDE\n- PMID:19952505 (fucoxanthin FX mutagenicity): EXCLUDE - different FX\n- PMID:23423894 (FX cloning method): EXCLUDE - laboratory method\n- PMID:37522672 (FX-11 LDHA inhibitor): EXCLUDE - FX-11 is an LDHA inhibitor drug\n- PMID:29219021 (Supartz FX hyaluronic acid): EXCLUDE - brand name\n- Gene2pubmed curated papers about coagulation Factor X: KEEP where mechanistic\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1983,\n      \"finding\": \"The complete amino acid sequence of the light chain of human coagulation Factor X was determined, revealing 139 residues including 11 gamma-carboxyglutamic acid (Gla) residues; residue 63 was identified as L-erythro-beta-hydroxyaspartic acid, a novel post-translational modification not previously described in proteins.\",\n      \"method\": \"Automated Edman degradation of peptides from chemical and enzymatic digests, confirmed by proton NMR and mass spectrometry\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct protein sequencing with multiple orthogonal chemical methods; foundational structural characterization\",\n      \"pmids\": [\"6871167\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1984,\n      \"finding\": \"cDNA sequencing of human Factor X established that it is synthesized as a single-chain polypeptide containing both light and heavy chains connected by an Arg-Lys-Arg tripeptide; the two chains are then generated by cleavage of internal peptide bonds and linked by a disulfide bond in plasma. The heavy chain active site shows high DNA sequence identity with prothrombin and Factor IX.\",\n      \"method\": \"cDNA library screening with anti-Factor X antibody, DNA sequencing of positive clones\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — complete cDNA sequencing establishing biosynthetic mechanism; foundational study\",\n      \"pmids\": [\"6587384\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1986,\n      \"finding\": \"The gene organization of human Factor X was characterized, revealing seven introns and eight exons whose boundaries are essentially identical to those in Factor IX and protein C genes, with each exon encoding a discrete structural/functional domain (Gla domain, EGF-like domains, activation peptide, serine protease domain). This organization strongly supports evolution of vitamin K-dependent coagulation factors from a common ancestral gene.\",\n      \"method\": \"Recombinant bacteriophage isolation, DNA sequencing to map intron/exon boundaries\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — complete gene sequencing with structural domain mapping; foundational\",\n      \"pmids\": [\"3768336\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"Factor Xa functions as a component of the prothrombinase complex, requiring cofactor Factor Va, phospholipid membrane surfaces, and calcium ions to efficiently cleave prothrombin to thrombin. Factor Xa's serine protease activity is the catalytic center of this complex.\",\n      \"method\": \"In vitro reconstitution of prothrombinase complex; kinetic enzyme assays\",\n      \"journal\": \"Annual review of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution assays, extensively replicated; foundational review summarizing established mechanism\",\n      \"pmids\": [\"3052293\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"The lipoprotein-associated coagulation inhibitor (LACI, later named TFPI) directly inhibits Factor Xa at or near its active site, forming a Factor Xa-LACI complex detectable by non-denaturing PAGE. This Xa-LACI complex is required for subsequent feedback inhibition of the Factor VIIa/tissue factor complex, requiring the Gla domain of Xa. Heparin accelerates Xa inhibition ~2.5-fold; phospholipid and Ca2+ slow it ~2.5-fold.\",\n      \"method\": \"Chromogenic substrate assays, bioassays, non-denaturing PAGE, SDS-PAGE complex visualization, use of Gla-domain-lacking BXa(-GD) construct\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzyme assays with mutagenesis/domain deletion and multiple orthogonal methods; foundational mechanistic paper\",\n      \"pmids\": [\"3422166\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"Tissue Factor Pathway Inhibitor (TFPI) regulates coagulation via a two-step mechanism: it first directly inhibits Factor Xa, then in a Factor Xa-dependent manner produces feedback inhibition of the Factor VIIa/tissue factor catalytic complex. This explains why both extrinsic and intrinsic coagulation pathways are clinically required for hemostasis.\",\n      \"method\": \"Kinetic inhibition assays, reconstituted coagulation system\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro with kinetic analysis; multiply replicated\",\n      \"pmids\": [\"2271516\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"The crystal structure of human des(1-45) Factor Xa (lacking the Gla domain) was solved at 2.2 Å resolution, revealing: the catalytic domain fold is similar to alpha-thrombin; the second EGF-like module makes contacts with the catalytic domain; the C-terminal Arg of the A-chain interacts in a substrate-like manner with the S1 specificity pocket of a neighboring molecule; and there is a Ca2+-binding site in the catalytic domain. The structure also showed that the region corresponding to the fibrinogen recognition site of thrombin has reversed electrical polarity in Factor Xa.\",\n      \"method\": \"X-ray crystallography at 2.2 Å resolution, R-value 0.168; automated Edman degradation for fragment identity\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution crystal structure with rigorous refinement; foundational structural paper\",\n      \"pmids\": [\"8355279\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Protein S directly binds Factor Xa (Kd ~18-19 nM) independent of activated protein C, and directly inhibits Factor Xa amidolytic activity (~50% inhibition at 33 nM protein S). Protein S also inhibits prothrombin conversion by Factor Xa in a phospholipid-independent, Ca2+-stimulated manner. Protein S inhibition of prothrombinase was 2.3-fold more potent in the presence of Factor Va, with ~8 nM protein S causing 50% inhibition.\",\n      \"method\": \"Ligand blotting, immobilized protein binding assays, fluid-phase binding with Kd determination, amidolytic activity assays, one-stage clotting time assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal binding and functional assays; direct Kd measurements; strong evidence\",\n      \"pmids\": [\"8146182\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1984,\n      \"finding\": \"Protein C inhibitor (from human plasma) inhibits Factor Xa with an inhibition constant (Ki) of 3.1 × 10⁻⁷ M. The inhibitor forms an enzyme-inhibitor complex (apparent Mr ~102,000 non-reduced) with Factor Xa; heparin (5-10 units/ml) accelerates inhibition of activated protein C ~30-fold and also accelerates Factor Xa inhibition. The complex can be dissociated by ammonia or hydroxylamine, releasing active enzyme.\",\n      \"method\": \"Kinetic inhibition assays, SDS-PAGE of enzyme-inhibitor complexes, 125I-labeled inhibitor autoradiography\",\n      \"journal\": \"Journal of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzyme kinetics with complex visualization and multiple proteases tested; rigorous\",\n      \"pmids\": [\"6323392\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"The 3.0 Å crystal structure of human des-Gla Factor Xa in complex with the synthetic inhibitor DX-9065a revealed two principal binding interactions: the naphthamidine group forms a salt bridge with Asp-189 in the S1 pocket, and the pyrrolidine ring binds in a unique aryl-binding site (S4). Unlike thrombin inhibitor complexes, Gly-216 (S3) does not contribute hydrogen bonds. The S2 site is blocked by Tyr-99, distinguishing Factor Xa from thrombin. The S4 site is lined by carbonyl oxygens that accommodate positive charges.\",\n      \"method\": \"X-ray crystallography at 3.0 Å resolution with synthetic inhibitor complex\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution crystal structure with inhibitor complex; defines substrate recognition mechanism\",\n      \"pmids\": [\"8939944\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"A Glu19Ala mutation in the Gla domain of Factor X causes symptomatic CRMred Factor X deficiency by specifically impairing activation via the Factor VIIa/tissue factor (extrinsic) pathway: complete activation of recombinant 19Ala-FX required 30-fold higher Factor VIIa/TF concentration than wild-type. Activation by Factor IXa/VIIIa or Russell's viper venom (RVV), and thrombin generation activity, were comparable to wild-type, demonstrating the Gla domain mediates specific interaction with the extrinsic pathway.\",\n      \"method\": \"Recombinant protein expression, activation assays with purified Factor VIIa/TF, FIXa/FVIIIa, and RVV; thrombin generation assays; prothrombin time and APTT plasma assays\",\n      \"journal\": \"Thrombosis and haemostasis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — recombinant protein with defined mutation, multiple orthogonal activation assays; strong mechanistic evidence\",\n      \"pmids\": [\"12195695\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Factor Xa generation through the tissue factor pathway is the central event of hemostasis, with thrombin playing multiple autocatalytic and feedback roles in its own generation and inhibition. Two Factor Xa-generating complexes exist: the extrinsic tenase (Factor VIIa/TF) for initiation, and the intrinsic tenase (Factor IXa/VIIIa) for amplification/propagation; stoichiometric inhibitors (TFPI, antithrombin) and dynamic mechanisms regulate the process.\",\n      \"method\": \"Review integrating in vitro reconstitution and kinetic data from multiple studies\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — review of extensively replicated reconstitution and kinetic studies; strong preponderance of evidence\",\n      \"pmids\": [\"12524220\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"A homozygous nonstop mutation (F10-Augusta) in the Factor X gene — combining an 8-bp insertion in 3'-genomic DNA and a 5-bp deletion in terminal exon 8 — results in complete absence of Factor X protein and severe hemorrhage. The mutant transcript lacks an in-frame stop codon, and its steady-state concentration is markedly lower than wild-type message, implicating the nonstop mRNA decay (NMD) surveillance pathway as the pathogenic mechanism reducing FX expression.\",\n      \"method\": \"Gene sequencing, RT-PCR, 3'-RACE, allele-specific RFLP assay comparing mutant vs. wild-type transcript levels in patient and heterozygous parent RNA\",\n      \"journal\": \"Thrombosis and haemostasis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — molecular characterization of patient mutation with mRNA surveillance mechanism; multiple molecular methods\",\n      \"pmids\": [\"18064309\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Coagulation Factor X (FX) binds to the adenovirus serotype 5 (Ad5) hexon protein — specifically to the hypervariable regions (HVRs) on the hexon surface — via an interaction between the FX Gla domain and hexon. The FX serine protease domain contains a heparin-binding exosite that mediates infection of hepatocytes. Cryo-electron microscopy and single-particle reconstruction localized the FX attachment site to the central depression at the top of the hexon trimer. Hexon-mutated virus with reduced FX binding failed to transduce hepatocytes in vivo.\",\n      \"method\": \"Affinity binding assays (FX binding affinity 229 pM by SPR), cryo-electron microscopy with single-particle image reconstruction, in vivo hepatocyte transduction with hexon-mutated virus\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — cryo-EM structure, affinity measurements, mutagenesis, in vivo validation; multiply replicated across two concurrent papers\",\n      \"pmids\": [\"18267072\", \"18391209\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Systematic mutagenesis identified specific amino acids on Ad5 hexon HVR5 and HVR7 critical for FX binding: mutation of 2 amino acids in HVR5 or 4 amino acids in HVR7 (or a single mutation at position 451 in HVR7) was sufficient to ablate FX-mediated liver transduction in vitro and in vivo. FX binding requires the hexon HVR5 and HVR7 regions, as demonstrated by domain swapping with Ad26 (which does not bind FX).\",\n      \"method\": \"Surface plasmon resonance (SPR) binding assays, domain swapping between Ad5 and Ad26, site-directed mutagenesis, in vitro gene delivery, in vivo liver transduction\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — mutagenesis combined with SPR, in vitro and in vivo functional assays; strong evidence\",\n      \"pmids\": [\"19429866\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Factor X expression is locally upregulated in fibrotic lung tissue (bronchial and alveolar epithelia) in human idiopathic pulmonary fibrosis and murine bleomycin models. Locally produced FXa drives myofibroblast differentiation in primary human lung fibroblasts via TGF-beta activation mediated through proteinase-activated receptor-1 (PAR1) and integrin αvβ5. Direct FXa inhibition attenuated bleomycin-induced pulmonary fibrosis in mice, establishing a causal mechanistic link.\",\n      \"method\": \"Immunostaining of human biopsy specimens, in vitro myofibroblast differentiation assay with recombinant FXa, PAR1/integrin αvβ5 inhibitor studies, in vivo bleomycin mouse model with FXa inhibitor treatment\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway (FXa→PAR1/αvβ5→TGF-β→myofibroblast) established with inhibitors, in vitro and in vivo validation\",\n      \"pmids\": [\"19652365\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"FX-binding ablated Ad5 vectors (with mutations abolishing hexon-FX interaction) show highly reduced liver transduction but preferentially localize to liver and spleen 1 hour post-injection, with spleen transduction (CD11c+, ER-TR7+, MAdCAM-1+ cells in the marginal zone) becoming more efficient at high doses. This demonstrates that FX binding is specifically required for hepatocyte transduction but not for initial hepatic/splenic biodistribution.\",\n      \"method\": \"In vivo biodistribution studies, immunohistochemistry with cell-type markers, transgene co-localization, macrophage depletion experiments\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo functional studies with FX-binding ablated vectors; mechanistically informative\",\n      \"pmids\": [\"20610817\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Factor X (FX) is upregulated in lung interstitial macrophages following gemcitabine chemotherapy, and activated FX (FXa) contributes to a pro-metastatic host response. Targeting FXa with an FXa inhibitor or F10 gene knockdown reduced chemotherapy-induced pro-metastatic effects, demonstrating that FXa in macrophages promotes breast cancer lung metastasis through interplay between coagulation and inflammation.\",\n      \"method\": \"Transgenic spontaneous breast cancer model, gemcitabine treatment, flow cytometry, CCR2 knockout, F10 gene knockdown with siRNA/shRNA, FXa inhibitor pharmacological treatment, in vivo metastasis quantification\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic and pharmacological evidence; single study but multiple orthogonal approaches\",\n      \"pmids\": [\"36976637\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"Human coagulation Factor X (F10) is a vitamin K-dependent serine protease synthesized as a single-chain precursor with Gla, EGF, and catalytic domains encoded by an 8-exon gene; it is activated by cleavage via the extrinsic (FVIIa/TF) or intrinsic (FIXa/FVIIIa) tenase complexes — with the Gla domain specifically required for extrinsic pathway activation — and then functions as the catalytic subunit of the prothrombinase complex (with FVa, phospholipid, and Ca²⁺) to convert prothrombin to thrombin; FXa activity is regulated by direct inhibition from TFPI (forming a FXa-TFPI-FVIIa/TF quaternary complex), protein S (Kd ~18 nM), protein C inhibitor, and antithrombin; structurally, its active site S1 pocket binds Asp-189, a unique S4 aryl-binding site lined by carbonyl oxygens accommodates positive charges, and Tyr-99 blocks the S2 site; beyond coagulation, locally expressed FXa signals through PAR1 and integrin αvβ5 to activate TGF-β and drive myofibroblast differentiation in lung fibrosis, and FXa in macrophages can promote tumor metastasis.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"The F10 gene encodes coagulation factor X (FX), a vitamin K-dependent serine protease whose Gla domain is specifically required for activation via the factor VIIa/tissue factor extrinsic pathway, as demonstrated by the Glu19Ala mutation that impairs extrinsic but not intrinsic pathway activation [PMID:12195695]. Nonstop mutations in F10 trigger mRNA decay and complete loss of FX protein, causing severe hemorrhagic disease [PMID:18064309]. Beyond hemostasis, FX is upregulated in lung interstitial macrophages after chemotherapy, and F10 knockdown or pharmacological FXa inhibition reduces chemotherapy-induced metastatic seeding in a breast cancer model, implicating F10 in coagulation-driven pro-metastatic inflammation [PMID:36976637].\",\n  \"teleology\": [\n    {\n      \"year\": 2002,\n      \"claim\": \"The structural basis for pathway-specific FX activation was resolved: the Gla domain residue Glu19 is selectively required for activation by the extrinsic (FVIIa/TF) but not intrinsic (FIXa/FVIIIa) pathway, establishing that the Gla domain discriminates between activating complexes.\",\n      \"evidence\": \"Recombinant Glu19Ala-FX expressed and tested in activation assays with FVIIa/TF, FIXa/FVIIIa, and RVV, plus plasma reconstitution\",\n      \"pmids\": [\"12195695\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural basis for Gla domain–TF/FVIIa interaction at atomic resolution not determined\",\n        \"Contribution of other individual Gla residues to pathway specificity not mapped\"\n      ]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"A mechanism linking F10 gene mutation to complete FX protein loss was identified: a nonstop mutation (F10-Augusta) eliminates the stop codon, triggering nonstop mRNA decay and explaining the severe hemorrhagic phenotype in a patient.\",\n      \"evidence\": \"Gene sequencing, RT-PCR, 3'-RACE, and allele-specific RFLP comparing mutant and wild-type transcript levels in patient and heterozygous parent\",\n      \"pmids\": [\"18064309\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Single patient/family study; prevalence of nonstop mutations among F10-deficiency cases unknown\",\n        \"Whether residual read-through protein is produced was not assessed at the protein level\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"A non-hemostatic role for FX was established: chemotherapy-induced F10 upregulation in lung interstitial macrophages promotes metastatic seeding, and both F10 knockdown and FXa inhibition reduce lung metastasis, linking the coagulation cascade to the pre-metastatic niche.\",\n      \"evidence\": \"Transgenic spontaneous breast cancer mouse model with F10 knockdown and FXa inhibitor treatment, macrophage and metastasis quantification\",\n      \"pmids\": [\"36976637\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Downstream signaling mechanism by which FXa in macrophages promotes metastasis not defined\",\n        \"Single study in one tumor model; generalizability to other cancers not tested\",\n        \"Whether thrombin generation or PAR signaling mediates the pro-metastatic effect is unresolved\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The precise mechanism by which macrophage-derived FXa promotes metastatic niche formation — whether through thrombin generation, PAR receptor signaling, or direct extracellular matrix effects — and whether FXa inhibitors have clinical anti-metastatic utility remain open questions.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No structural model of FX in complex with its macrophage-expressed substrates or receptors\",\n        \"No clinical studies testing FXa inhibitors specifically for anti-metastatic efficacy\",\n        \"Full spectrum of F10 loss-of-function mutations and genotype-phenotype correlations not systematically mapped\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [6]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [5, 6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [6, 7]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"F7\",\n      \"F3\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"Coagulation Factor X is a vitamin K-dependent serine protease that serves as the convergence point of the extrinsic and intrinsic coagulation pathways and, upon activation to Factor Xa, forms the catalytic subunit of the prothrombinase complex (with Factor Va, phospholipid, and Ca²⁺) to convert prothrombin to thrombin [PMID:3052293, PMID:12524220]. Synthesized as a single-chain precursor containing Gla, EGF-like, and serine protease domains, FX undergoes intracellular processing to a disulfide-linked two-chain zymogen; its Gla domain, which carries 11 γ-carboxyglutamic acid residues and a β-hydroxyaspartic acid at position 63, is specifically required for activation by the extrinsic tenase (FVIIa/tissue factor), as demonstrated by the Glu19Ala mutation that selectively impairs this pathway [PMID:6871167, PMID:6587384, PMID:12195695]. FXa activity is regulated by TFPI (which first inhibits FXa then uses the FXa–TFPI complex for feedback inhibition of FVIIa/TF), protein S (Kd ~18 nM, direct FXa inhibition independent of activated protein C), protein C inhibitor, and antithrombin [PMID:3422166, PMID:2271516, PMID:8146182, PMID:6323392]. Beyond hemostasis, locally expressed FXa in lung tissue signals through PAR1 and integrin αvβ5 to activate TGF-β and drive myofibroblast differentiation in pulmonary fibrosis, and FXa upregulated in lung interstitial macrophages promotes breast cancer metastasis [PMID:19652365, PMID:36976637].\",\n  \"teleology\": [\n    {\n      \"year\": 1983,\n      \"claim\": \"Determination of the complete light-chain amino acid sequence resolved the primary structure of the Gla domain and identified a novel post-translational modification (β-hydroxyaspartic acid at residue 63), establishing the chemical basis for FX's calcium- and membrane-binding properties.\",\n      \"evidence\": \"Automated Edman degradation with NMR and mass spectrometry confirmation of purified human FX light chain\",\n      \"pmids\": [\"6871167\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional role of β-hydroxyaspartate at position 63 not established\", \"Three-dimensional arrangement of Gla residues unknown at this stage\"]\n    },\n    {\n      \"year\": 1984,\n      \"claim\": \"cDNA sequencing revealed that FX is synthesized as a single-chain precursor processed by cleavage of an internal Arg-Lys-Arg tripeptide into disulfide-linked light and heavy chains, establishing the biosynthetic pathway and confirming homology with other vitamin K-dependent proteases.\",\n      \"evidence\": \"cDNA library screening with anti-FX antibody and full-length sequencing\",\n      \"pmids\": [\"6587384\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Intracellular processing site(s) and responsible protease(s) not identified\", \"Regulation of FX expression not addressed\"]\n    },\n    {\n      \"year\": 1986,\n      \"claim\": \"Gene structure analysis showed eight exons with boundaries matching Factor IX and protein C, demonstrating that each exon encodes a discrete functional domain and supporting the model that vitamin K-dependent coagulation factors evolved from a common ancestral gene.\",\n      \"evidence\": \"Bacteriophage cloning and DNA sequencing of the entire F10 gene with intron/exon mapping\",\n      \"pmids\": [\"3768336\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Promoter and transcriptional regulation of F10 not characterized\", \"No functional correlation between individual exon-encoded domains and activity\"]\n    },\n    {\n      \"year\": 1988,\n      \"claim\": \"Reconstitution experiments established that FXa is the catalytic subunit of the prothrombinase complex and that TFPI (LACI) inhibits FXa directly, with the resulting FXa–TFPI complex required for feedback inhibition of FVIIa/TF — defining the central regulatory logic of coagulation initiation.\",\n      \"evidence\": \"In vitro prothrombinase reconstitution with kinetic assays; chromogenic and bioassay inhibition studies with Gla-domain-deleted FXa\",\n      \"pmids\": [\"3052293\", \"3422166\", \"2271516\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of FXa–TFPI interaction unknown\", \"In vivo stoichiometry and kinetics of quaternary complex not determined\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"The first crystal structure of human Factor Xa (des-Gla, 2.2 Å) revealed the catalytic domain fold, inter-domain contacts between EGF2 and the protease domain, a catalytic-domain Ca²⁺ site, and reversed electrostatic polarity at the fibrinogen-recognition-equivalent surface compared to thrombin — explaining FXa's distinct substrate specificity.\",\n      \"evidence\": \"X-ray crystallography at 2.2 Å resolution\",\n      \"pmids\": [\"8355279\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length structure including Gla domain not obtained\", \"No co-crystal with FVa or prothrombin substrate\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Demonstration that protein S directly binds FXa (Kd ~18 nM) and inhibits its amidolytic and prothrombinase activities independently of activated protein C established a previously unrecognized anticoagulant mechanism operating through direct FXa regulation.\",\n      \"evidence\": \"Ligand blotting, fluid-phase binding assays, amidolytic and clotting assays with purified protein S and FXa\",\n      \"pmids\": [\"8146182\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Binding interface on FXa not mapped\", \"Physiological relevance relative to APC-dependent pathway not quantified in vivo\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Co-crystal structure of FXa with inhibitor DX-9065a defined the active-site architecture — S1 pocket salt bridge with Asp-189, a unique S4 aryl-binding site lined by carbonyl oxygens, and S2 blockage by Tyr-99 — providing the structural framework that distinguishes FXa from thrombin for selective drug design.\",\n      \"evidence\": \"X-ray crystallography at 3.0 Å with synthetic inhibitor complex\",\n      \"pmids\": [\"8939944\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structure with macromolecular inhibitor (TFPI, antithrombin)\", \"Dynamics of S4 pocket accommodation of diverse ligands not addressed\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"The Glu19Ala Gla-domain mutation demonstrated that a single residue change selectively abolishes extrinsic-pathway activation while leaving intrinsic-pathway activation intact, proving the Gla domain mediates a specific molecular interaction with the FVIIa/TF complex rather than simply anchoring FX to membranes.\",\n      \"evidence\": \"Recombinant FX mutant expression with activation assays using purified FVIIa/TF, FIXa/FVIIIa, and RVV\",\n      \"pmids\": [\"12195695\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Exact contact residues between Gla domain and TF/FVIIa not mapped structurally\", \"Other Gla-domain residues contributing to extrinsic pathway specificity not systematically tested\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Discovery that the FX Gla domain binds adenovirus serotype 5 hexon (Kd ~229 pM) and that the FX serine protease domain contains a heparin-binding exosite mediating hepatocyte entry revealed an unexpected role for a coagulation factor as a blood-borne bridge enabling viral liver tropism.\",\n      \"evidence\": \"SPR binding, cryo-EM single-particle reconstruction, hexon-mutant Ad5 with ablated FX binding, in vivo hepatocyte transduction assays\",\n      \"pmids\": [\"18267072\", \"18391209\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular receptor on hepatocytes engaged by FX-coated virus not identified\", \"Whether other vitamin K-dependent factors can substitute for FX in vivo not tested\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Two key mechanistic advances: (1) mutagenesis of hexon HVR5/HVR7 defined the minimal FX-binding determinants on the adenovirus surface, and (2) locally expressed FXa in fibrotic lung was shown to drive myofibroblast differentiation via PAR1 and integrin αvβ5–mediated TGF-β activation, establishing a non-hemostatic pro-fibrotic signaling axis.\",\n      \"evidence\": \"Domain swapping/site-directed mutagenesis of Ad5/Ad26 hexon with SPR and in vivo transduction; FXa treatment of primary human lung fibroblasts with PAR1/αvβ5 inhibitors; bleomycin mouse fibrosis model with FXa inhibitor\",\n      \"pmids\": [\"19429866\", \"19652365\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream signaling cascade between PAR1/αvβ5 and TGF-β activation not fully delineated\", \"Whether FXa's fibrotic role extends beyond the lung not established\", \"Hepatocyte receptor for FX-Ad5 complex remains unidentified\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identification of FX upregulation in lung interstitial macrophages after chemotherapy, with FXa promoting breast cancer lung metastasis, extended the non-hemostatic biology of FXa to tumor–immune crosstalk.\",\n      \"evidence\": \"Transgenic breast cancer model with gemcitabine, flow cytometry, F10 knockdown (siRNA/shRNA), FXa inhibitor, in vivo metastasis quantification\",\n      \"pmids\": [\"36976637\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which macrophage-derived FXa promotes metastasis (PAR signaling, ECM remodeling, or other) not defined\", \"Generalizability beyond breast cancer lung metastasis not tested\", \"Single study awaiting independent replication\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: the structural basis of FXa interaction with FVa in the assembled prothrombinase complex, the identity of the hepatocyte receptor engaged by FX-coated adenovirus, the full signaling pathway linking macrophage FXa to metastatic niche formation, and whether FXa's non-hemostatic functions (fibrosis, metastasis) share a common PAR-dependent mechanism.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No high-resolution structure of full prothrombinase complex\", \"Hepatocyte receptor for FX–Ad5 unknown\", \"Common vs. distinct signaling of FXa in fibrosis and metastasis not compared\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [3, 6, 7, 9, 11]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [3, 8, 9]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [0, 3, 10]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [1, 3, 7, 11]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [3, 15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [3, 4, 5, 7, 10, 11]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [15, 17]}\n    ],\n    \"complexes\": [\n      \"Prothrombinase complex (FXa/FVa/phospholipid/Ca²⁺)\",\n      \"FXa–TFPI–FVIIa/TF quaternary complex\"\n    ],\n    \"partners\": [\n      \"F5\",\n      \"F2\",\n      \"TFPI\",\n      \"PROS1\",\n      \"F7\",\n      \"F3\",\n      \"SERPINA5\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}